|

Multiple Sclerosis Clinical Trials in New York, NY

35 recruiting studies within 50 miles

Phase
Trial Phase Dist.
NYSCF Scientific Discovery Biobank—<1 mi
A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune DisordersPhase 1<1 mi
Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVOPhase 1<1 mi
RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical IllnessesPhase 2<1 mi
TSC Biosample Repository and Natural History Database—<1 mi
Home-Based Transcranial Direct Current Stimulation (tDCS) for Depression in Multiple Sclerosis (MS)Phase 2<1 mi
A Study of AZD0120 in Autoimmune DiseasesPhase 1<1 mi
PHENOGENE-1A (Cromolyn) Treatment in Patients With Mild to Moderate ALSPhase 2<1 mi
A Study of the MIND Diet for Persons With Multiple SclerosisN/A<1 mi
A Palliative Care Model Impact on Knowledge and AttitudesN/A<1 mi
Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)Phase 3<1 mi
Study of COYA 302 for the Treatment of ALSPhase 2<1 mi
Genes and Environment in Multiple Sclerosis—<1 mi
Eccentric Exercise and Fatigue in Multiple Sclerosis—<1 mi
Effect of Cooling on Balance Performance in Multiple Sclerosis—<1 mi
A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)—<1 mi
Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of UblituximabPhase 3<1 mi
Vancomycin Study in Multiple Sclerosis (MS)Phase 1<1 mi
An Open-label Study of AZD0120 in Adults With Multiple SclerosisPhase 1<1 mi
Ocrelizumab Discontinuation in Relapsing Multiple SclerosisPhase 4<1 mi
A Study Evaluating the Safety and Efficacy of KITE-363 in Relapsed/Refractory Autoimmune Neurologic DiseasesPhase 1<1 mi
Targeting Agonists of Glucagon-like Peptide-1 Receptor for Multiple SclerosisPhase 2<1 mi
Longitudinal Cortical Demyelination in Multiple Sclerosis and Related Disorders—<1 mi
Gait Adaptation StudyEarly 19 mi
AMT-260 Gene Therapy Study in Adults With Unilateral Refractory Mesial Temporal Lobe EpilepsyPhase 1/212 mi
Study to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple SclerosisPhase 313 mi
Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.Phase 313 mi
Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple SclerosisPhase 313 mi
Investigating the Effects of Wearable Robotic Exoskeleton for Improving Mobility and Cognition in Persons With MSN/A14 mi
A Study of Orelabrutinib in Patients With Primary Progressive Multiple SclerosisPhase 317 mi
Testing the Feasibility of Computer-based Cognitive Training in Individuals with Multiple Sclerosis Living in the CommunityN/A20 mi
A Novel Combinatory Approach to Maximize Functional Recovery of Learning and Memory in Multiple SclerosisN/A20 mi
Silodosin for Urinary Symptoms in Female Patients With Multiple SclerosisPhase 426 mi
Neurologic Stem Cell Treatment StudyN/A45 mi
Risk of Progressive Multifocal Leukoencephalopathy Among Patients With Multiple Sclerosis Exposed to Zeposia—48 mi

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.